chintan parekh

Has grant

Assistant Professor

University of Southern California
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

About

Chintan Parekh is an Assistant Professor at the University of Southern California, USA. His research primarily focuses on pediatric oncology, specifically the efficacy and safety of chemotherapy regimens in childhood acute myeloid leukemia and T-cell acute lymphoblastic leukemia. He has also investigated the impact of COVID-19 on children and young adults with cancer.

Recent Grants

Grant: Close

Role of the long non-coding RNA DANCR in T-ALL

Open Date: 2016-09-01

Close Date: 2018-11-01

Grant: Close

Role of the long non-coding RAN DANCR in T-ALL

Open Date: 2016-07-01

Close Date: 2017-06-01

Grant: Close

Role of BCL11B in the pathogenesis of T cell acute lymphoblastic leukemia

Open Date: 2016-07-01

Close Date: 2017-06-30

Grant: Close

Role of BCL11B in the pathogenesis of T cell acute lymphoblastic leukemia

Open Date: 2015-07-01

Close Date: 2016-06-30

Grant: Close

Role of BCL11B in the pathogenesis of T cell acute lymphoblastic leukemia

Open Date: 2012-07-01

Close Date: 2015-06-30

Articles (9)

Year:

2025

Chimeric antigen receptor (CAR) T-cell therapy has remarkably succeeded in treating lymphoblastic leukemia. However, its success in acute myeloid leukemia (AML) remains elusive because of the risk of on-target off-tumor toxicity to hematopoietic stem/progenitor cells (HSPC) and insufficient T-cell persistence and longevity. Using a SynNotch circuit, we generated a high-precision “IF-THEN” gated logical circuit against the combination of CD33 and CD123 AML antigens and demonstrated antitumor efficacy against AML cell lines and patient-derived xenografts. Unlike constitutively expressed CD123 CAR-T cells, those expressed through the CD33 SynNotch circuit could preserve HSPCs and lower the risk of on-target off-tumor hematopoietic toxicity. These gated CAR-T cells exhibited lower expression of exhaustion markers (PD-1, TIM-3, LAG-3, and CD39), higher frequency of memory T cells (CD62L+CD45RA+), and enhanced expansion. Although targeting AML, the moderated circuit CAR signal also helped mitigate cytokine release syndrome, potentially addressing one of the ongoing challenges in CAR-T immunotherapy. Significance: Our study demonstrates the use of “IF-THEN” SynNotch-gated CAR-T cells targeting CD33 and CD123 in AML reduces off-tumor toxicity. This strategy enhances T-cell phenotype, improves expansion, preserves HSPCs, and mitigates cytokine release syndrome—addressing critical limitations of existing AML CAR-T therapies.

Year:

2025

Year:

2025

Year:

2025

Chimeric antigen receptor (CAR) T-cell therapy has remarkably succeeded in treating lymphoblastic leukemia. However, its success in acute myeloid leukemia (AML) remains elusive because of the risk of on-target off-tumor toxicity to hematopoietic stem/progenitor cells (HSPC) and insufficient T-cell persistence and longevity. Using a SynNotch circuit, we generated a high-precision “IF-THEN” gated logical circuit against the combination of CD33 and CD123 AML antigens and demonstrated antitumor efficacy against AML cell lines and patient-derived xenografts. Unlike constitutively expressed CD123 CAR-T cells, those expressed through the CD33 SynNotch circuit could preserve HSPCs and lower the risk of on-target off-tumor hematopoietic toxicity. These gated CAR-T cells exhibited lower expression of exhaustion markers (PD-1, TIM-3, LAG-3, and CD39), higher frequency of memory T cells (CD62L + CD45RA + ), and enhanced expansion. Although targeting AML, the moderated circuit CAR signal also helped mitigate cytokine release syndrome, potentially addressing one of the ongoing challenges in CAR-T immunotherapy. Significance: Our study demonstrates the use of “IF-THEN” SynNotch-gated CAR-T cells targeting CD33 and CD123 in AML reduces off-tumor toxicity. This strategy enhances T-cell phenotype, improves expansion, preserves HSPCs, and mitigates cytokine release syndrome—addressing critical limitations of existing AML CAR-T therapies.

Year:

2025

Little is known about the efficacy of COVID‐19 vaccines during acute lymphoblastic leukemia therapy (ALL); data for COVID‐19 vaccine immune responses in pediatric leukemia remain sparse. We conducted a single center study of patients aged 5–25 years undergoing ALL chemotherapy who received COVID‐19 vaccination. Twenty‐one patients were enrolled; efficacy was evaluable in 20. Twenty were vaccinated while receiving chemotherapy. Twenty received the BNT162b2 mRNA vaccine. Spike reactive antibodies (S‐IgG) and/or T‐cells (SRT) were detected in 16 of 20 (80%) vaccinated patients; 13 (65%) and 9 (45%) were positive for S‐IgG and SRT, respectively. Six (30%) showed both spike reactive B and T‐cell responses. Eleven of the 13 with S‐IgG positivity were negative for anti‐Nucleocapsid IgG, an antibody profile consistent with a vaccine induced immune response. All 13S‐IgG+ patients showed neutralizing antibodies. SRT included CD4+ (7) and CD8+ (6) T‐cells; both CD4+ and CD8+ SRT were seen in 4. SRT were multifunctional (producing multiple cytokines) in most patients (8 of 9); 4 showed SRT with triple cytokine and B‐cell co‐stimulatory responses, indicating a multimodal adaptive immune response. Immune responses were seen among patients vaccinated in the settings of lymphopenia (6 of 12) intensive chemotherapy (3 of 4), and Peg allergy (6 of 8). Sequencing revealed public CD4+ and CD8+ TCR sequences reactive to epitopes across the spike protein. In conclusion, COVID‐19 vaccination induced B and/or T‐cell responses in a majority of children and young adults undergoing ALL chemotherapy.

Year:

2024

Year:

2023

Year:

2022

Year:

2021

Collaborators (6)

Andrew Doan

-

UNITED STATES
View details

Michael A. Pulsipher

University of Utah Health Huntsman Cancer Institute

UNITED STATES
View details

Alexandra Kovach

Director, Hematopathology; Associate Professor, Keck School of Medicine of University of Southern California

Children's Hospital of Los Angeles

UNITED STATES
View details

Yong-Mi Kim

Professor of Pediatrics and Pathology (with Tenure)

University of Southern California Keck School of Medicine

UNITED STATES
View details

Shahab Asgharzadeh

University of Southern California

UNITED STATES
View details

Sorana Morrissy

Assistant Professor

University of Calgary

CANADA
View details